Search results
Results from the WOW.Com Content Network
Sitagliptin, sold under the brand name Januvia among others, is an anti-diabetic medication used to treat type 2 diabetes. [8] In the United Kingdom it is listed as less preferred than metformin or a sulfonylurea. [9] It is taken by mouth. [8] It is also available in the fixed-dose combination medication sitagliptin/metformin (Janumet, Janumet ...
Clinical researches have shown that sitagliptin and vildagliptin do not have the side effects that tend to follow type 2 diabetes treatment, e.g. weight gain and hyperglycemia, but however, other side effects have been observed, including upper respiratory tract infections, sore throat and diarrhea. [5]
Drugs belonging to this class are: Sitagliptin [6] (FDA approved 2006, marketed by Merck & Co. as Januvia) Vildagliptin [7] (EU approved 2007, marketed in the EU by Novartis as Galvus) Saxagliptin (FDA approved in 2009, marketed as Onglyza) Linagliptin (FDA approved in 2011, marketed as Tradjenta by Eli Lilly and Company and Boehringer ...
“There are myriad commonly used medications that promote weight gain, including diabetes medication, antidepressants, and high blood pressure medications,” says M. Daniela Hurtado, M.D., Ph.D ...
For premium support please call: 800-290-4726 more ways to reach us
Related: Ozempic FAQ: All About the Drug Being Used for Weight Loss — Yes, You Will Likely Gain Weight When You Stop Taking It Alcohol and Drug Addiction. In the same way that GLP-1 drugs reduce ...
In the United States, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. [5] [6]In the European Union, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in people with type 2 diabetes; in combination with a sulfonylurea as an adjunct to diet and exercise "in people ...
The Food and Drug Administration warned Thursday that diabetes drugs might be elevating the rate of pancreatic cancer. Investors shouldn't be surprised. Nor particularly worried. We've known for ...